GeneDx Lifts Profit Outlook to $12 Million as Documentation Push Slows Volume

By Marcus Bennett

GeneDx posted third-quarter revenue of $123.1 million and raised its full-year adjusted net income outlook to at least $12 million, while cutting its test volume growth forecast because of stricter payer documentation requirements. The genetic testing company now expects full-year results at the low end of its $475 million to $490 million revenue range.

The trade-off is deliberate. Management now requires more payer documentation before genome testing begins — a change designed to improve reimbursement, but one that slows orders moving through the lab and has lifted cancellation, downgrade and delayed-start rates.

Chief Executive Officer Katherine Stueland said demand remained strong and described the changes as part of a push toward profitable growth.

What do the numbers show?

The company resulted more than 32,100 exome and genome tests in the quarter ended Sept. 30, 2026. Adjusted gross margin (a profitability measure excluding items such as stock compensation) rose to 72%, and adjusted net income reached $8.6 million.

Blended average reimbursement climbed roughly 5% from the second quarter to $3,436 per test. Chief Financial Officer Kevin Feeley attributed the gain to better genome collections and a testing mix shift toward exome, which carries a higher average contracted and reimbursement rate.

President Mark Gardner said the company's review found that 62% of exome and genome denials were administrative or procedural, while the remaining 38% involved clinical necessity disputes or patients not covered by payer policies. Collecting documentation earlier is the direct countermeasure.

Accessions (orders received) grew 28% year over year, versus 25% growth in reported test volume. During the question-and-answer session, Gardner said much of that gap reflects tests delayed by a few days rather than permanently lost volume. Feeley said he expects substantially all of the difference to move through the process over time, though not necessarily within one quarter.

Underlying outpatient genome collection rate rose to 36% from 32% in the second quarter. The exome collection rate held at approximately 32%. Feeley said some of the genome improvement reflected health plans following Carelon's expanded coverage policy, with a smaller contribution from Medi-Cal.

Stueland said the documentation impact concentrated among genetics customers, who are more likely to order genome tests. Feeley added that orders received electronically — primarily through Epic — showed better document collection and reimbursement results than other orders.

What changed in the guidance?

The company now guides to full-year adjusted gross margin of approximately 71% and adjusted net income of at least $12 million, both raised. Volume expectations moved the other way: full-year exome and genome volume growth is now seen at at least 28%, and exome and genome revenue growth at at least 17%.

Fourth-quarter projections:

• Total revenue of at least $135 million
• $121 million in exome and genome revenue on 34,500 resulted tests
• Average reimbursement of approximately $3,500 per test
• Adjusted gross margin of at least 71%
• Adjusted net income of approximately $12 million

Management gave no formal 2027 guidance. Feeley said approximately 45% of total revenue is exposed to changes under the Protecting Access to Medicare Act, or PAMA (a law that ties lab payment rates to market data), and the company expects a mid-single-digit headwind to total revenue next year. He said improved collections could offset, or more than offset, that pressure.

Where do costs and new markets go from here?

Genome testing represented 26% of outpatient insurance-based volume in the third quarter, down from 32% in the second. Feeley called the shift deliberate near-term mix management, not an effort to minimize genome use, and expects genome's share to rise again as product enhancements and unit economics improve.

Genome cost per test fell 43% from a year earlier, though it remains significantly higher than exome cost. The company sees a path to cutting genome cost per test by at least several hundred dollars over the next several quarters through lower reagent costs, and over a longer period through greater use of artificial intelligence and machine learning.

GeneDx is also pushing beyond its core geneticist and pediatric neurologist customers. Gardner said the general pediatrician sales team, which entered the field in February, is already paying for itself. He clarified that management expects general pediatrics to contribute more unit volume growth in 2027 than any other individual segment — not more than all other segments combined.

Gardner also said prenatal and neonatal intensive care markets are growing faster than the company overall. GeneDx recently launched an early-access program for long-read sequencing and is working with clinical experts on criteria for using the technology.

For practitioners, the takeaway is a company trading near-term volume velocity for reimbursement quality — and for now, the margin math is winning.